Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
John Funkhouser
AddedMar 31, 2024
UpdatedMay 31, 2026
John Funkhouser

John Funkhouser

CEO, Pharmanetics

CrunchbaseLinkedIn

John Funkhouser's Career

Pharmanetics
Pharmanetics

Morrisville, NC, US

CEO· C-Suite · Management
Myocardial Solutions
Myocardial Solutions

Morrisville, NC, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

John Funkhouser's Career

Pharmanetics
Pharmanetics
Public$9.5M741998Morrisville, NC, US
CEO· C-Suite · Management

Leadership at Pharmanetics

James B. FarinholtJames B. FarinholtBoard Member
John K PirotteJohn K PirotteBoard Member
Richard M Johnston \"Dick\"Richard M Johnston \"Dick\"Board Member

Similar to Pharmanetics

ThromboVisionThromboVisionHouston, TX, USDiagnostic Solutionsest. 2006ThromboVisionHouston, TX, US · est. 2006

ThromboVision: A biomedical firm offering cost-effective cardiovascular diagnostic solutions for healthier lives.

Series A · $4M3
Rapidscan Pharma SolutionsRapidscan Pharma SolutionsLos Altos, CA, USStress Agentsest. 2010Rapidscan Pharma SolutionsLos Altos, CA, US · est. 2010

Rapidscan Pharma Solutions Inc. develops pharmacological stress agents for diagnosing cardiovascular diseases.

Series A · $2.4M7
Kantum PharmaKantum PharmaConcord, NH, USDiagnostics, Therapeuticsest. 2016Kantum PharmaConcord, NH, US · est. 2016

Kantum: Innovating critical care with targeted AKI therapy and novel diagnostic tests.

Series A · $3.5M9
PhoresaPhoresaSeattle, WA, USDiagnostic Testsest. 2014PhoresaSeattle, WA, US · est. 2014

Phoresa: Innovating diagnostic tech for efficient, cost-effective patient care in infectious diseases.

Angel · $225k30
Myocardial Solutions
Myocardial Solutions
Series A$31.2M372016Morrisville, NC, US
Board Member· Board

Leadership at Myocardial Solutions

Nael OsmanNael OsmanCo-Founder

Similar to Myocardial Solutions

CardioWiseCardioWiseFayetteville, AR, USHealthcare Softwareest. 2012CardioWiseFayetteville, AR, US · est. 2012

CardioWise, Inc.: Pioneering cardiac imaging analysis software for comprehensive heart health insights.

Angel · $820k8
HeartVistaHeartVistaPalo Alto, CA, USMedical Imagingest. 2012HeartVistaPalo Alto, CA, US · est. 2012

HeartVista: Streamlining MRI diagnostics with one-click, machine learning-enhanced imaging technology.

Series A · $8.7M16
MyoCardioCareMyoCardioCareFort Collins, CO, USMedical Devicesest. 2009MyoCardioCareFort Collins, CO, US · est. 2009

MyoCardioCare: Innovating patient-centric medical devices for heart care and life-saving solutions.

Angel · $24.6k7
Cardiac InsightCardiac InsightBellevue, WA, USMedical Devices, Softwareest. 2010Cardiac InsightBellevue, WA, US · est. 2010

Cardiac Insight: Innovating ECG diagnostics with advanced wearable sensors and automated software.

Public · $32.3M44

John Funkhouser's Similar Executives & Operators

Achmad ZakyAchmad ZakyCo-Founder · BukalapakLau Eng BoonLau Eng BoonBoard Member · BukalapakWillix HalimWillix HalimCEO · BukalapakNugroho HerucahyonoNugroho HerucahyonoCo-Founder · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakBo ZhangBo ZhangCo-Founder · DiDiWILL WEI CHENGWILL WEI CHENGBoard Member · DiDi

People Similar to John Funkhouser

Ronald GoldRonald GoldBoard Member · NJ BioJonathan SacksJonathan SacksCEO · PharmAdvaNeil McFarlaneNeil McFarlaneCEO · Zevra TherapeuticsHoyoung HuhHoyoung HuhFounder & CEO · pH PharmaJohn FowlerJohn FowlerCEO · Pharmaceutics InternationalNakul PasrichaNakul PasrichaCEO · PharmaSecure